Evaluation of the components of the insulin-like growth factors system in GH-deficient adults: Effects of twelve-month rhGH treatment

Hormone and Metabolic Research

Volumn 38, Issue 5, 2006, Pages 352-355

  Ferrante, E ^a   Giavoli, C ^a   Porretti, S ^a   Vassallo, E ^a   Ronchi, C L ^a   Lania, A G ^a   Beck Peccoz, P ^a   Spada, Anna ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

GH deficiency; GH therapy; IGFBPs; IGFs

Indexed keywords

HUMAN GROWTH HORMONE; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG EFFECT; DRUG SAFETY; FEMALE; GROWTH HORMONE DEFICIENCY; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROVOCATION TEST; TREATMENT DURATION;

ADULT; ANTHROPOMETRY; BODY MASS INDEX; CARRIER PROTEINS; FEMALE; GLYCOPROTEINS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; SOMATOMEDINS;

EID: 33745005095     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-925402     Document Type: Article

References (26)

1. Daughaday WH, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 1989; 10: 68-91
2. Barreca A, Ponzani P, Arvigo A, Voci A, Giordano G, Minuto F. Functions and regulation of the acid-labile subunit of the 150 K complex. Prog Growth Factor Res 1995; 6: 231-239
3. Twigg SM, Baxter RC. Insulin-like growth factor (IGF-)binding protein 5 forms an alternative ternary complex with IGFs and Acid-labile sub-unit. J Biol Chem 1998; 273: 6074-6079
4. Baxter RC. Inhibition of the insulin-like growth factor (IGF-)IGF-binding protein interaction. Horm Res 2001; 55 (Suppl 2): 68-72
5. De Boer H, Block GJ, Popp-Snijders C, Stuurman L, Baxter RC, van der Veen E. Monitoring of growth hormone replacement therapy in adults, based on measurements of serum markers. J Clin Endocrinol Metab 1996; 81: 1371-1377
6. Juul A, Møller S, Mosfeldt-Laursen E, Højby Rasmussen M, Scheike T, Pedersen SA, Kastrup KW, Yu H, Mistry J, Rasmussen S, Müller J, Henrisken J, Skakkebaek NE. The acid-labile subunit of human tenary insulin-like growth factor binding complex in serum: hepatosplacnic release, diurnal variation, circulating concentrations in healthy subjects, and diagnostic use in patients with growth hormone deficiency. J Clin Endocrinol Metab 1998; 81: 4408-4415
7. Yu H, Mistry J, Nikar MJ, Khosravi MJ, Diamandis A, van Doorn J, Juul A. Insulin-like growth factors (IGF-I, free IGF and IGF-II) and insulin-like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6 and ALS) in blood circulation. J Clin Lab Anal 1999; 13: 166-172
8. Shimatsu A, Nakamura Y, Ihara C, Mizuta H, Murabe H. Serum Insulin-like growth factor-II (IGF-II) levels in patients with acromegaly and growth hormone deficiency: correlation with IGF-I and IGF binding protein-3. Endocr J 1996; 43 (Suppl): S71-73
9. Aguiar-Oliveira MH, Gill MS, de Barretto ES, Alcantara MR, Miraki-Moud F, Menezes CA, Souza AH, Martinelli CE, Pereira FA, Salvatori R, Levine MA, Shalet SM, Camacho-Hubner C, Clayton PE. Effect of severe growth hormone (GH) deficiency due to a mutation in the GH-releasing hormone receptor on insulin-like growth factors (IGFs), IGF-binding proteins, and ternary complex formation throughout life. J Clin Endocrinol Metab 1999; 84: 4118-4126
10. Belgorosky A, Rivarola MA. Insulin-like growth factors binding protein (IGFBP)-3-bound IGF-I and IGF-II in growth hormone deficiency. Horm Res. 1999; 52: 60-65
11. Fernholm R, Bramnert M, Hagg E, Hilding A, Baylink DJ, Mohan S, Thoren M. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease. J Clin Endocrinol Metab 2000; 85: 4104-4112
12. Ezzat S, Fear S, Gaillard RC, Gayle C, Landy H, Marcovitz S, Mattioni T, Nussey S, Rees A, Svanberg E. Gender-specific responses of lean body composition and non-gender-specific cardiac function improvement after GH replacement in GH-deficient adults. J Clin Endocrinol Metab 2002; 87: 2725-2733
13. Tillmann V, Patel L, Gill MS, Whatmore AJ, Price DA, Kibirige MS, Wales JK, Clayton PE. Monitoring serum insulin-like growth factor-I (IGF-I), IGF binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and leptin during growth hormone treatment for disordered growth. Clin Endocrinol 2000; 53: 329-336
14. Ghigo E, Aimaretti G, Giannotti L, Bellone J, Arvat E, Camanni F. New approach to the diagnosis of growth hormone deficiency in adults. Eur J Endocrinol 1996; 134: 352-356
15. Segal KR, Van Loan M, Fitzgerald PI, Hodgdon JA, Van Itallie TB. Lean body mass estimation by bioelectrical impedance analysis: a four-site cross validation study. Am J Clin Nutr 1988; 47: 7-14
16. Pichard C, Kyle UG, Bracco D, Slosman DO, Morabia A, Schutz Y. Reference values of fat-free and fat masses by bioelectrical impedance analysis in 3393 healthy subjects. Nutrition 2000; 16: 245-254
17. Giavoli C, Cappiello V, Porretti S, Ronchi CL, Orsi E, Beck-Peccoz P, Arosio M. Growth hormone therapy in GH-deficient adults: continuous vs. alternate-days treatment. Horm Metab Res 2003; 35: 557-561
18. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351: 1393-1396
19. Ma J, Pollak M, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ. Prospective study of colorectal cancer risk in men and plasma levels of insulin like growth factor (IGF)-I and IGF binding protein-3. J Natl Cancer Inst 1999; 91: 620-625
20. Manousos O, Souglakos J, Bosetti C, Tzonou A, Chatzidakis V, Trichopoulos D, Adami HO, Mantzoros C. IGF-I and IGF-II in relation to colorectal cancer. Int J Cancer 1999; 83: 15-17
21. Li L, Yu H, Schumacher F, Casey G, Witte JS. Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes Control 2003; 14: 721-726
22. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF-)I, IGF binding protein-3 and cancer risk: systematic review and meta-regression analysis. Lancet 2004; 363: 1346-1353
23. Jenkins PJ, Bustin SA. Evidence for a link between IGF-I and cancer. Eur J Endocrinol 2004; 151 (Suppl 1): S17-22
24. Toretsky JA, Helman LJ. Involvement of IGF-II in human cancer. J Endocrinol 1996; 149: 367-372
25. Khandawala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000; 21: 215-244
26. LeRoith D, Roberts CT jr. The insulin-like growth factor system and cancer. Cancer Letter 2003; 195: 127-137